VOLITIONRX LTD
VNRXNYSE AMERICAN🏆 #3789 by market capEarnings Aug 19US Equity
$566.92▲ $20.69 (+3.65%)
Simulated price1h—
24h▲ 3.6%
7d—
14d—
30d—
1y—
🏦Market Cap
$9M
Small Cap
📈Revenue Growth (YoY)
+88.5%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
3.4x
Fair
Otter Score
61
Fair
No chart data available for VNRX.
Trading Snapshot
- Day Range
- $561.13 – $569.80
- 52-Week Range
- $0.69 – $15.10
- Volume
- $4.89B
- Avg Volume
- $4.08B
- Shares Outstanding
- 11.6M
- Next Earnings
- Sep 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $665,682
- P/E Ratio
- —
- P/S Ratio
- 3.4x
- EPS (TTM)
- $-4.22
- Dividend Yield
- —
Why Investors Own VNRX
- ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 60% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$3M▲ +21.0% YoY
Gross Margin (TTM)
59.6%▲ +2.8% YoY
Operating Income (TTM)
$409,630▲ +21.0% YoY
Free Cash Flow (TTM)
$206,087▲ +21.0% YoY
About VOLITIONRX LTD
A company profile for VOLITIONRX LTD isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
61/100
Analyst Price Target
ⓘAverage Target
$646.54
▲ +14.0% Upside
High Target$737.60
Low Target$520.30
Based on 15 analysts
Latest News & Updates
🚀
Reuters·2h ago
VOLITIONRX LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift VNRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
VOLITIONRX LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.